John J.  Trizzino net worth and biography

John Trizzino Biography and Net Worth

CFO of Novavax
Mr. Trizzino is executive vice president, chief business officer, chief commercial officer and interim chief financial officer with responsibility for global commercial strategy and execution and oversight of IT, investor and public relations, and corporate affairs. He has broad experience in publicly held companies and in vaccines, with previous roles overseeing commercialization, policy, strategy, business development, financing, and investor and public relations. Since rejoining Novavax in 2014, he has held roles of increasing responsibility, including chief financial officer and senior vice president of commercial operations. Mr. Trizzino served as CEO of Immunovaccine in 2011, successfully leading the company into clinical development while securing the funding commitments required to advance the company’s lead candidate. Earlier in his career, Mr. Trizzino held leadership roles at several companies with a focus in infectious disease vaccine markets, including MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.

What is John J. Trizzino's net worth?

The estimated net worth of John J. Trizzino is at least $67,790.25 as of September 14th, 2021. Mr. Trizzino owns 8,217 shares of Novavax stock worth more than $67,790 as of February 18th. This net worth evaluation does not reflect any other assets that Mr. Trizzino may own. Additionally, Mr. Trizzino receives a salary of $670,550.00 as CFO at Novavax. Learn More about John J. Trizzino's net worth.

How old is John J. Trizzino?

Mr. Trizzino is currently 64 years old. There are 6 older executives and no younger executives at Novavax. The oldest executive at Novavax is Mr. Richard P. Crowley, Executive VP & COO, who is 67 years old. Learn More on John J. Trizzino's age.

What is John J. Trizzino's salary?

As the CFO of Novavax, Inc., Mr. Trizzino earns $670,550.00 per year. There are 2 executives that earn more than Mr. Trizzino. The highest earning executive at Novavax is Mr. John Charles Jacobs M.B.A., President, CEO & Director, who commands a salary of $1,330,000.00 per year. Learn More on John J. Trizzino's salary.

How do I contact John J. Trizzino?

The corporate mailing address for Mr. Trizzino and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at ir@novavax.com. Learn More on John J. Trizzino's contact information.

Has John J. Trizzino been buying or selling shares of Novavax?

John J. Trizzino has not been actively trading shares of Novavax during the past quarter. Most recently, John Trizzino sold 7,501 shares of the business's stock in a transaction on Tuesday, September 28th. The shares were sold at an average price of $209.92, for a transaction totalling $1,574,609.92. Learn More on John J. Trizzino's trading history.

Who are Novavax's active insiders?

Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.

Are insiders buying or selling shares of Novavax?

During the last twelve months, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 76,462 shares worth more than $985,852.80. The most recent insider tranaction occured on December, 31st when Director James F Young sold 5,400 shares worth more than $43,200.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.

Information on this page was last updated on 12/31/2024.

John J. Trizzino Insider Trading History at Novavax

John J. Trizzino Buying and Selling Activity at Novavax

This chart shows John Trizzino's buying and selling at Novavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

Novavax Company Overview

Novavax logo
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $8.25
Low: $8.22
High: $8.54

50 Day Range

MA: $8.72
Low: $7.83
High: $10.82

2 Week Range

Now: $8.25
Low: $3.81
High: $23.86

Volume

3,678,378 shs

Average Volume

4,240,173 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14